Impax Asset Management Group plc lowered its stake in Catalent Inc (NYSE:CTLT) by 90.7% in the 4th quarter, HoldingsChannel reports. The fund owned 35,791 shares of the company’s stock after selling 348,512 shares during the quarter. Impax Asset Management Group plc’s holdings in Catalent were worth $1,116,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Quantamental Technologies LLC purchased a new position in Catalent during the 4th quarter worth $47,000. Bremer Trust National Association purchased a new position in Catalent during the 4th quarter worth $54,000. Enlightenment Research LLC purchased a new position in Catalent during the 4th quarter worth $56,000. First Bank & Trust boosted its holdings in Catalent by 13.9% during the 4th quarter. First Bank & Trust now owns 4,600 shares of the company’s stock worth $143,000 after acquiring an additional 563 shares during the last quarter. Finally, Ramsey Quantitative Systems purchased a new position in Catalent during the 4th quarter worth $194,000. Institutional investors and hedge funds own 98.79% of the company’s stock.

Shares of NYSE:CTLT opened at $42.45 on Thursday. The company has a current ratio of 2.08, a quick ratio of 1.63 and a debt-to-equity ratio of 1.36. The stock has a market capitalization of $6.21 billion, a P/E ratio of 26.70, a P/E/G ratio of 2.34 and a beta of 1.70. Catalent Inc has a fifty-two week low of $29.23 and a fifty-two week high of $46.43.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, February 5th. The company reported $0.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.08. The company had revenue of $623.00 million for the quarter, compared to the consensus estimate of $608.38 million. Catalent had a net margin of 5.48% and a return on equity of 17.42%. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.45 EPS. On average, analysts expect that Catalent Inc will post 1.69 EPS for the current year.

A number of research firms have issued reports on CTLT. TheStreet raised shares of Catalent from a “c” rating to a “b-” rating in a report on Wednesday, February 6th. First Analysis reaffirmed an “outperform” rating and set a $49.00 price objective on shares of Catalent in a report on Tuesday, March 5th. Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Thursday, February 7th. Morgan Stanley set a $46.00 price objective on shares of Catalent and gave the stock a “buy” rating in a report on Monday, December 3rd. Finally, ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $47.88.

In related news, SVP William Downie sold 7,315 shares of the business’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $42.00, for a total value of $307,230.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Lance Miyamoto sold 43,619 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $42.49, for a total transaction of $1,853,371.31. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2019/03/21/catalent-inc-ctlt-shares-sold-by-impax-asset-management-group-plc.html.

Catalent Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Story: The mechanics of the bid-ask spread in trading

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.